Not a Member?
Email this page
Send the page ""
to a friend, relative, colleague or yourself.
Separate multiple email address with a comma
We do not record any personal information entered above.
Thank you. Your email has been sent.
Active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine in persons ≥50 yrs of age and persons aged ≥2 yrs who are at increased risk for pneumococcal disease.
Active immunization against serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
≥50 Years:Single 0.5mL dose
≥2 Years and at Increased Risk for Pneumococcal Disease:Single 0.5mL dose
Administer into the deltoid muscle or lateral mid-thighDo not mix w/ other vaccines in the same syringe or vial
Single-Dose and Multidose Vials Withdraw 0.5mL from the vial using a sterile needle and syringe
Single-Dose, Prefilled SyringePackage does not contain a needle; attach a sterile needle to prefilled syringe by twisting in a clockwise direction until the needle fits securely on the syringe
RevaccinationAdvisory Committee on Immunization Practices has recommendations for revaccination against pneumococcal disease for persons at high risk who were previously vaccinated w/ Pneumovax 23; routine revaccination of immunocompetent persons previously vaccinated w/ a 23-valent vaccine is not recommended
Inj: 0.5mL [prefilled syringe, single-dose vial, multidose vial]
Do not inject intravascularly or intradermally. Defer vaccination in patients with moderate or severe acute illness. Caution with severely compromised cardiovascular (CV) and/or pulmonary function in whom a systemic reaction would pose a significant risk. Does not replace the need for antibiotic prophylaxis (eg, PCN) against pneumococcal infection; antibiotic prophylaxis should not be discontinued after vaccination in patients who require antibiotic prophylaxis. Response to vaccine may be diminished in immunocompromised individuals. May not be effective in preventing pneumococcal meningitis in patients with chronic CSF leakage resulting from congenital lesions, skull fractures, or neurosurgical procedures. Will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. Caution in elderly.
Local inj-site reactions (eg, pain, soreness, tenderness, swelling, induration, erythema), asthenia, fatigue, myalgia, headache.
Persons receiving immunosuppressive therapies may have a diminished immune response to the vaccine. Reduced immune response to zoster vaccine live reported; consider separation of vaccinations by at least 4 weeks.
Category C, caution in nursing.
Vaccine; induces antibodies that enhance opsonization, phagocytosis, and killing of pneumococci by leukocytes and other phagocytic cells.
Assess for moderate/severe acute illness, severely compromised CV and/or pulmonary function, chronic CSF leakage, vaccination history, history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine, immunocompromised conditions, pregnancy/nursing status, and for possible drug interactions.
Monitor for hypersensitivity reactions and other adverse reactions.
Inform of potential benefits/risks of vaccination. Inform that the vaccine may not offer 100% protection from pneumococcal infection. Instruct to report any serious adverse reactions to physician.